Rational approaches towards lead optimization of kinase inhibitors: The issue of specificity

Current Pharmaceutical Design

Volumn 19, Issue 26, 2013, Pages 4714-4738

  Badrinarayan, Preethi ^a   Sastry, G Narahari ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

DFG loop; FBDD; Kinase specificity; Lead design; p38 MAP kinase; Strategies

Indexed keywords

ADENOSINE TRIPHOSPHATE; AXITINIB; BENZAMIDE DERIVATIVE; CRIZOTINIB; DASATINIB; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE P38; NILOTINIB; OXINDOLE; PAZOPANIB; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PURINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; RUXOLITINIB; SORAFENIB; SULFONAMIDE; SUNITINIB; TEMSIROLIMUS; UNINDEXED DRUG; VANDETANIB;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONFORMATION; CONFORMATIONAL TRANSITION; DRUG BINDING; DRUG SPECIFICITY; DRUG TARGETING; ENZYME ACTIVE SITE; FINGER DERMATOGLYPHICS; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; MOLECULE; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN INTERACTION;

ALLOSTERIC REGULATION; DRUG DESIGN; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; SUBSTRATE SPECIFICITY;

EID: 84881329806     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319260005     Document Type: Article

References (238)

1. Mannig G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298: 1912-34.
2. Cohen P. Protein kinases-the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002; 1: 309-15.
3. Janardhan S, Srivani P, Sastry GN. Choline kinase: An important target for cancer. Curr Med Chem 2006; 13: 1169-86.
4. Ravindra GK, Achaiah G, Sastry GN. Novel targets for antiinflammatory and anti-arthritic agents. Curr Pharm Des 2006; 12: 2437-54.
5. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9: 28-39.
6. Dar AC, Shokat KM. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Annu Rev Biochem 2011; 80: 769-95.
7. Grant SK. Therapeutic protein kinase inhibitors. Cell Mol Life Sci 2009; 66: 1163-77.
8. PDB: 2HYY. Cowan-Jacob SW, Fendrich G, Floersheimer A, et al. Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Acta Crystallogr D Biol Crystallogr 2007; 63: 80-93.
9. PDB: 2ITY. Yun CH, Boggon TJ, Li Y, et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007; 11: 217-27.
10. PDB: 1M17. Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002; 277: 46265-72.
11. PDB: 1UWH. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signalling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855-67.
12. PDB: 3G0E. Gajiwala KS, Wu JC, Christensen J, et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci USA 2009; 106: 1542-7.
13. PDB: 2GQG. Tokarski JS, Newitt JA, Chang CY, et al. The structure of dasatinib (BMS-354825) bound to activated abl kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006; 66: 5790-7.
14. PDB: 1XKK. Wood, ER, Truesdale AT, McDonald OB, Yuan D, Hassell A. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004; 64: 6652-9.
15. PDB: 3CS9. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-41.
16. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005; 23: 5294-304.
17. PDB: 3CJF. Harris PA, Boloor A, Cheung M, et al. Discovery of 5-[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 2008; 51: 4632-40.
18. Apweiler R, Bairoch A, Wu CH, et al. UniProt: the Universal Protein knowledgebase. Nucleic Acids Res 2004; 32: D115-9.
19. Berman HM, Westbrook J, Feng Z, et al. The Protein Data Bank. Nucleic Acids Res 2000; 28: 235-42.
20. Knox C, Law V, Jewison T, et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 2011; 39: D1035-41.
21. Morphy R. Selectively Nonselective Kinase inhibition: Striking the right balance. J Med Chem 2010; 53: 1413-37.
22. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007; 408: 297-315.
23. Vieth M, Sutherland JJ, Robertson DH, Campbell RM. Kinomics: Characterizing the therapeutically validated kinase space. Drug Discov Today 2005; 10: 839-46.
24. Chen J, Zhang X, Fernandez A. Molecular basis for specificity in the druggable kinome: sequence-based analysis. 2007; 23: 563-72.
25. Smyth LA, Collins I. Measuring and interpreting the selectivity of protein kinase inhibitors. J Chem Biol 2009; 2: 131-51.
26. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006; 2: 358-64.
27. Zuccotto F, Ardini E, Casale E, Angiolini M. Through the "Gatekeeper door": exploiting the active kinase conformation. J Med Chem 2010; 53: 2681-94.
28. Collins I, Workman P. Design and development of signal transduction inhibitors for cancer treatment: Experience and challenges with kinase targets. Curr Signal Transduct Ther 2006; 1: 13-23.
29. Fitzgerald CE, Patel SB, Becker JW, et al. Structural basis for p38 MAP kinase quinazolinone and pyridol-pyrimidine inhibitor pecificity. Nat Struct Biol 2003; 10: 764-9.
30. Vulpetti A, Bosotti R. Sequence and structural analysis of kinase ATP pocket residues. Farmaco 2004; 59: 759-65.
31. Soliva R, Gelpi JL, Almansa C, Virgili M, Orozco M. Dissection of the recognition properties of p38 MAP kinase. Determination of the binding mode of a new pyridinyl-heterocycle inhibitor family. J Med Chem 2007; 50: 283-93.
32. Bikker JA, Brooijmans N, Wissner A, Mansour TS. Kinase domain mutations in cancer: Implications for small molecule drug design strategies. J Med Chem 2009; 52: 1493-509.
33. Badrinarayan P, Sastry GN. Sequence, structure, and active site analyses of p38 MAP kinase: Exploiting DFG-out conformation as a strategy to design new type II leads. J Chem Inf Model 2010; 51: 115-29.
34. Telesco SE, Shih AJ, Jia F, Radhakrishnan R. A multiscale modeling approach to investigate molecular mechanisms of pseudokinase activation and drug resistance in the HER3/ErbB3 receptor tyrosine kinase signaling network. Mol Biosyst 2011; 7: 2066-80.
35. Gleeson MP, Gleeson D. QM/MM as a tool in fragment based drug discovery. A cross-docking, rescoring study of kinase inhibitors. J Chem Inf Model 2009; 49: 1437-48.
36. Vreven T, Byun KS, Komaromi I, et al. Combining quantum mechanics methods with molecular mechanics methods in ONIOM. J Chem Theory Comput 2006; 2: 815-26.
37. Yang Y, Shen Y, Liu H, Yao X. Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38 MAP Kinase. J Chem Inf Model 2011; 51: 3235-46.
38. Badrinarayan P, Sastry GN. Virtual high-throughput screening in new lead identification. Comb Chem High T Scr 2011; 14: 840-60.
39. Reddy AS, Pati SP, Kumar PP, Pradeep HN, Sastry GN. Virtual screening in drug discovery-A computational perspective. Curr Prot Peptide Sci 2007; 8: 329-51.
40. Pierce AC, Rao G, Bemis GW. BREED: Generating novel inhibitors through hybridization of known ligands. Application to CDK2, p38, and HIV Protease. J Med Chem 2004; 47: 2768-75.
41. Shih KC, Lin CY, Chi HC, et al. Design of novel FLT-3 inhibitors based on dual-layer 3D-QSAR model and fragment-based compounds in silico. J Chem Inf Model 2011; 52: 146-55.
42. Srivani P, Sastry GN. Potential choline kinase inhibitors: a molecular modeling study of bis-quinolinium compounds. J Mol Graph Model 2009; 27: 676-88.
43. Brylinski M, Skolnick J. Comprehensive structural and functional characterization of the human kinome by protein structure modeling and ligand virtual screening. J Chem Inf Model 2010; 50: 1839-54.
44. Vogtherr M, Saxena K, Hoelder S, et al. NMR characterization of kinase p38 dynamics in free and ligand bound forms. Angew Chem Int Ed 2006; 45: 993-7.
45. Badrinarayan P, Sastry GN. Virtual screening filters for the design of type II p38 MAP kinase inhibitors: A fragment based library generation approach. J Mol Graph Modell 2012; 34: 89-100.
46. Vieth M, Higgs RE, Robertson DH, Shapiro M, Gragg EA, Hemmerle H. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim Biophys Acta 2004; 1697: 243-57.
47. Briem H, Gunther J. Classifying "Kinase Inhibitor-Likeness" by using machine-learning methods. Chem Bio Chem 2005; 6: 558-66.
48. Huang D, Zhou T, Lafleur K, Nevado C, Caflisch A. Kinase selectivity potential for inhibitors targeting the ATP binding site: A network analysis. Bioinformatics 2010; 26: 198-204.
49. Lessel U, Wellenzohn B, Lilienthal M, Claussen H. Searching fragment spaces with feature trees. J Chem Inf Model 2009; 49: 270-9.
50. Deng Z, Chuaqui C, Singh J. Structural interaction fingerprint (SIFt): A novel method for analyzing three-dimensional proteinligand binding interactions. J Med Chem 2004; 47: 337-44.
51. Xing Li, Shieh HS, Selness SR, et al. Structural bioinformaticsbased prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804. Biochemistry 2009; 48: 6402-11.
52. Adams JA. Kinetic and catalytic mechanisms of protein kinases. Chem Rev 2001; 101: 2271-90.
53. Liao JJL. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J Med Chem 2007; 50: 409-24.
54. Patel RY, Doerksen RJ. Protein kinase-inhibitor database: structural variability of and inhibitor interactions with the protein kinase P-loop. J Proteome Res 2010; 9: 4433-42.
55. Guimarães CR, Rai BK, Munchhof MJ, et al. Understanding the impact of the P-loop conformation on kinase selectivity. J Chem Inf Model 2011; 51: 1199-204.
56. Kornev AP, Taylor SS. Defining the conserved internal architecture of a protein kinase. Biochim Biophys Acta 2010; 1804: 440-4.
57. Barouch-Bentov R, Che J, Lee CC, et al. A conserved salt bridge in the G loop of multiple protein kinases is important for catalysis and for in vivo Lyn function. Mol Cell 2009; 33: 43-52.
58. Nolen B, Taylor S, Ghosh G. Regulation of protein kinases: controlling activity through activation segment conformation. Mol Cell 2004; 15: 661-75.
59. PDB: 1A9U. Shan Y, Seeliger MA, et al. A conserved protonationdependent switch controls drug binding in the Abl kinase. Proc Natl Acad Sci USA 2009; 106: 139-44.
60. PDB: 1KV2. Pargellis C, Tong L, Churchill L, et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 2002; 9: 268-72.
61. Cherry M, Williams DH. Recent kinase and kinase inhibitor X-ray structures: Mechanisms of inhibition and selectivity insights. Curr Med Chem 2004; 11: 663-73.
62. Cuenda A, Rouse J, Doza YN, et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 1995; 364: 229-33.
63. Caffrey DR, Lunney EA, Moshinsky DJ. Prediction of specificitydetermining residues for small-molecule kinase inhibitors. BMC Bioinformatics 2008; 9: 491-505.
64. Shewchuk L, Hassell A, Wisely B, et al. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclindependent kinase 2 and p38 kinase. J Med Chem 2000; 43: 133-8.
65. Alaimo PJ, Knight ZA, Shokat, KM. Targeting the gatekeeper residue in phosphoinositide 3-kinases. Bioorg Med Chem 2005; 13: 2825-36.
66. Perot S, Sperandio O, Miteva MA, Camproux AC, Villoutreix BO. Druggable pockets and binding site centric chemical space: A paradigm shift in drug discovery. Drug Discov Today 2010; 15: 656-67.
67. Wang Z, Canagarajah BJ, Boehm JC, et al. Structural basis of inhibitor selectivity in MAP kinases. Structure 1998; 6: 1117-28.
68. Natarajan SR, Heller ST, Nam K, et al. p38 MAP kinase inhibitors. Part 6: 2-Arylpyridazin-3-ones as templates for inhibitor design. Bioorg Med Chem Lett 2006; 16: 5809-13.
69. Schindler T, Sicheri F, Pico A, Gazit A, Levitzki A, Kuriyan J. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol Cell 1999; 3: 639-48.
70. Mortlock A, Keen NJ, Jung FH, et al. Progress in the development of selective inhibitors of Aurora kinases. Curr Top Med Chem 2005; 5: 199-213.
71. Rabiller M, Getlik M, Klüter S, et al. Proteus in the world of proteins: conformational changes in protein kinases. Arch Pharm 2010; 343: 193-206.
72. Hardy JA, Wells JA. Searching for new allosteric sites in enzymes. Curr Opin Struct Biol 2004; 14: 706-15.
73. PDB: 1WBO. Hartshorn MJ, Murray CW, Cleasby A, Frederickson M, Tickle IJ, Jhoti H. Fragment-based lead discovery using X-ray crystallography. J Med Chem 2005; 48: 403-13.
74. PDB: 1WBT. Gill AL, Frederickson M, Cleasby A, et al. Identification of novel p38alpha MAP kinase inhibitors using fragmentbased lead generation. J Med Chem. 2005; 48: 414-26.
75. PDB: 1E9H. Davies TG, Tunnah P, Meijer L, et al. Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. Structure 2001; 9: 389-97.
76. PDB: 1HCL. Schulze-Gahmen U, Brandsen J, Jones HD, et al. Multiple modes of ligand recognition: crystal structures of cyclindependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins 1995; 22: 378-91.
77. Noronha G, Cao J, Chow CP, et al. Inhibitors of ABL and the ABL-T315I mutation. Curr Top Med Chem 2008; 8: 905-21.
78. Bartova I, Otyepka M, Kriz Z, Koca J. Activation and inhibition of cyclin-dependent kinase-2 by phosphorylation; a molecular dynamics study reveals the functional importance of the glycine-rich loop. Protein Sci 2004; 13: 1449-57.
79. Kumar P, Joshi DC, Akif M, Akhter Y, Hasnain SE, Mande SC. Mapping conformational transitions in cyclic AMP receptor protein: crystal structure and normal-mode analysis of Mycobacterium tuberculosis apo-cAMP receptor protein. Biophys J 2010; 98: 305-14.
80. Kannan N, Haste N, Taylor SS, Neuwald AF. The hallmark of AGC kinase functional divergence is its C-terminal tail, a cis-acting regulatory module. Proc Natl Acad Sci USA. 2007; 104: 1272-7.
81. PDB: 1CM8. Bellon S, Fitzgibbon MJ, Fox T, Hsiao HM, Wilson KP. The structure of phosphorylated p38gamma is monomeric and reveals a conserved activation-loop conformation. Structure 1999; 7: 1057-65.
82. Ahn YM, Clare M, Ensinger CL, et al. Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region. Bioorg Med Chem Lett 2010; 20: 5793-8.
83. Raaf J, Issinger OG, Niefind K. First inactive conformation of CK2 alpha, the catalytic subunit of protein kinase CK2. J Mol Biol 2009; 386: 1212-1.
84. Nagar B, Bornmann WG, Pellicena P, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002; 62: 4236-43.
85. Pellicena P, Kuriyan J. Protein-protein interactions in the allosteric regulation of protein kinases. Curr Opin Struct Biol 2006; 16: 702-9.
86. Hardy JA, Lam J, Nguyen JT, O'Brien T, Wells J. Discovery of an allosteric site in the caspases. Proc Natl Acad Sci USA 2004; 101: 12461-6.
87. Freire E. Can allosteric regulation be predicted from structure? Proc Natl Acad Sci USA 2000; 97: 11680-2.
88. Suel GM, Lockless SW, Wall MA, Ranganathan R. Evolutionarily conserved networks of residues mediate allosteric communication in proteins. Nat Struct Biol 2003; 10: 59-69.
89. Lichtarge O, Bourne HR, Cohen FE. An evolutionary trace method defines binding surfaces common to protein families. J Mol Biol 1996; 257: 342-58.
90. Kesner TF, Elcock AH. Computational sampling of a cryptic drug binding site in a protein receptor: Explicit solvent molecular dynamics and inhibitor docking to p38 MAP Kinase. J Mol Biol 2006; 359: 202-14.
91. Knighton DR, Zheng JH, Ten-Eyck LF, et al. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate regulated protein kinase. Science 1991; 253: 407-14.
92. Zhang J, Adrián FJ, Jahnke W, et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 2010; 463: 501-6.
93. Barnett SF, Defeo-Jones D, Fu S, et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J 2005; 385: 399-408.
94. Betzi S, Alam R, Martin M, et al. Discovery of a potential allosteric ligand binding site in CDK2. ACS Chem Biol 2011; 6: 492-501.
95. Shan Y, Kim ET, Eastwood MP, Dror RO, Seeliger MA, Shaw DE. How does a drug molecule find its target binding site? J Am Chem Soc 2011; 133: 9181-3.
96. Jones S, Thornton JM. Searching for functional sites in protein structures. Curr Opin Chem Biol 2004; 8: 3-7.
97. Kinnings SL, Jackson RM. Binding site similarity analysis for the functional classification of the protein kinase family. J Chem Inf Model 2009; 49: 318-29.
98. Shi Z, Resing KA, Ahn NG. Networks for the allosteric control of protein kinases. Curr Opin Struct Biol 2006; 16: 686-92.
99. Eswaran J, Knapp S. Insights into protein kinase regulation and inhibition by large scale structural comparison. Biochim Biophys Acta 2010; 1804: 429-32.
100. Fedorov O, Marsden B, Pogacic V, et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci USA 2007; 104: 20523-8.
101. Johnson LN. Protein kinase inhibitors: contributions from structure to clinical compounds. Q Rev Biophys 2009; 42: 1-40.
102. Noble ME, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science 2004; 303: 1800-5.
103. Thaimattam R, Banerjee R, Miglani R, Iqbal J. Johnson LN. Protein kinase inhibitors: structural insights into selectivity. Curr Pharm Des 2007; 13: 2751-65.
104. Chow LQ, Eckhardt SG. Sunitinib: From rational design to clinical efficacy. J Clin Oncol 2007; 25: 884-96.
105. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2: 471-8.
106. Mohammadi M, McMahon G, Sun L, et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 1997; 276: 955-60.
107. Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003; 46: 1116-9.
108. Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997; 57: 4838-48.
109. Barker AJ, Gibson KH, Grundy W, et al. Studies leading to the identification of ZD1839 (Iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001; 11: 1911-4.
110. Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration drug approval summary gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004; 10: 1212-8.
111. Tevaarwerk AJ, Kolesar JM. Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther 2009; 2: 2332-48.
112. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
113. Steinberg M. Dasatinib: A tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther 2007; 29: 2289-308.
114. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658-61.
115. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinibresistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531-41.
116. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinibresistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542-51.
117. DeRemer DL, Ustun C, Natarajan K. Nilotinib: A secondgeneration tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clinical Therapeutics. 2008; 30: 1956-75.
118. O'Hare T, Eide CA, Deininger MWN. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. BLOOD 2007; 110: 2242-9.
119. Weiss MM, Harmange JC, Polverino AJ, et al. Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors. J Med Chem 2008; 51: 1668-80.
120. Scapin G, Patel SB, Lisnock J, Becker JW, LoGrasso PV. The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity. Chem Biol 2003; 10: 705-12.
121. Ohren JF, Chen H, Pavlovsky A, et al. Adrian, Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 2004; 11: 1192-7.
122. Cohen MS, Zhang C, Shokat KM, Taunton J. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 2005; 308: 1318-21.
123. Leproult E, Barluenga S, Moras D, Wurtz JM, Winssinger N. Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors. J Med Chem 2011; 54: 1347-55.
124. Knight ZA, Shokat KM. Features of selective kinase inhibitors. Chem Biol 2005; 12: 621-37.
125. Blencke S, Zech B, Engkvist O, et al. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem Biol 2004; 11: 691-01.
126. Eyers PA, Craxton M, Morrice N, Cohen P, Goedert M. Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem Biol 1998; 5: 321-8.
127. Liu Y, Bishop A, Witucki L, et al. Structural basis for selective inhibition of Src family kinases by PP1. Chem Biol 1999; 6: 671-8.
128. Shah K, Liu Y, Deirmengian C, Shokat KM. Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates. Proc Natl Acad Sci USA 1997; 94: 3565-70.
129. Blencke S, Ullrich A, Daub H. Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J Biol Chem 2003; 278: 15435-40.
130. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-80.
131. Bishop AC, Ubersax JA, Petsch DT, et al. A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature 2000; 407: 395-401.
132. Choi HG, Ren P, Adrian F, et al. A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl. J Med Chem 2010 Aug 12; 53: 5439-48.
133. Tong L, Pav S, White DM, et al. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat Struct Biol 1997; 4: 311-6.
134. Wilson KP, McCaffrey PG, Hsiao K, et al. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem Biol 1997; 4: 423-31.
135. Ghose AK, Herbertz T, Pippin DA, Salvino JM, Mallamo JP. Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery. J Med Chem 2008; 5: 5149-71.
136. Chen H, Ma J, Li W, et al. A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol Cell 2007; 27: 717-30.
137. Wrobleski ST, Doweyko AM. Structural comparison of p38 inhibitor-protein complexes: A review of recent p38 inhibitors having unique binding interactions. Curr Top Med Chem 2005; 5: 1005-16.
138. Goldstein DM, Kuglstatter A, Lou Y, Soth MJ. Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem 2010; 53: 2345-53.
139. Gunasekaran K, Gomathia L, Ramakrishnan C, Chandrasekhar J, Balaram P. Conformational interconversions in peptide beta-turns: analysis of turns in proteins and computational estimates of barriers. J Mol Biol 1998; 284: 1505-16.
140. Meanwell NA. Synopsis of some recent tactical application of bioisosteres in drug design. J Med Chem 2011; 54: 2529-91.
141. Herberich B, Cao GQ, Chakrabarti PP, et al. Discovery of highly selective and potent p38 inhibitors based on a phthalazine scaffold. J Med Chem 2008; 51: 6271-9.
142. Wu B, Wang HL, Pettus L, et al. Discovery of pyridazinopyridinones as potent and selective p38 mitogen-activated protein kinase inhibitors. J Med Chem 2010; 53: 6398-411.
143. Reddy AS, Amarnath HSD, Bapi RS, Sastry GM, Sastry GN. Protein ligand interaction database (PLID): Datamining analysis of structure-function relationships. Comp Biol Chem 2008; 32: 387-90.
144. Bissantz C, Kuhn B, Stahl M. A medicinal chemist's guide to molecular interactions. J Med Chem 2010, 53: 5061-84.
145. Pierce AC, Sandretto KL, Bemis GW. Kinase inhibitors and the case for CHO hydrogen bonds in protein-ligand binding. Proteins 2002; 49: 567-76.
146. Pierce AC, ter Haar E, Binch HM, Kay DP, Patel SR, Li P. CHO and CHN hydrogen bonds in ligand design: a novel quinazolin-4-ylthiazol-2-ylamine protein kinase inhibitor. J Med Chem 2005; 48: 1278-81.
147. Panigrahi SK. Strong and weak hydrogen bonds in protein-ligand complexes of kinases: a comparative study. Amino Acids 2008; 34: 617-33.
148. Foloppe N, Fisher LM, Howes R, et al. Structure-based design of novel Chk1 inhibitors: Insights into hydrogen bonding and proteinligand affinity. J Med Chem 2005; 48: 4332-45.
149. Voth AR, Ho PS. The role of halogen bonding in inhibitor recognition and binding by protein kinases. Curr Top Med Chem 2007; 7: 1336-48.
150. Grant SK, Lunney EA. Voth AR, Khuu P, Oishi K, Ho PS. Kinase inhibition that hinges on halogen bonds. Chem Biol 2011; 18: 3-4.
151. Voth AR, Khuu P, Oishi K, Ho PS. Halogen bonds as orthogonal molecular interactions to hydrogen bonds. Nat Chem 2009; 1: 74-9.
152. Marcotte DJ, Liu YT, Arduini RM, et al. Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases. Protein Sci 2010; 19: 429-39.
153. Dougherty DA. Cation-interactions in chemistry and biology: a new view of benzene, Phe, Tyr, and Trp. Science 1996; 271: 163-8.
154. 4 +] interactions with the aromatic motifs of naturally occurring amino acids: A theoretical study. J Phys Chem A 2005; 109: 8893-903.
155. Reddy AS, Sastry GM, Sastry GN. Cation-Aromatic Database. Proteins: Struc, Func, Bioinfo. 2007; 67: 1179-84.
156. Filomia F, Rienzo FD, Menziani MC. Insights into MAPK p38 DFG flip mechanism by accelerated molecular dynamics. Bioorg Med Chem 2010; 18: 6805-12.
157. Purushotham U, Vijay D, Sastry GN. A computational investigation and the conformational analysis of Dimers, Anions, Cations and Zwitterions of L-Phenylalanine. J Comput Chem 2012; 33: 44-59.
158. Purushotham U, Sastry GN. Exploration of conformational and quantum chemical investigation of L-Tyrosine dimers, anions, cations and zwitterions. Theo Chem Acc 2012; 131: 1093-103.
159. Burley SK, Petsko GA. Amino-aromatic interactions in proteins. FEBS Lett. 1986; 203: 139-43.
160. Laufer SA, Hauser DRJ, Domeyer DM, Kinkel K, Liedtke AJ. Design, synthesis, and biological evaluation of novel tri-and tetrasubstituted imidazoles as highly potent and specific atp-mimetic inhibitors of p38 MAP kinase: Focus on optimized interactions with the enzyme's surface-exposed front region. J Med Chem 2008; 51: 4122-49.
161. 2ID: An analysis of aromatic β-networks in proteins. Int. J Biol Macromol 2011; 48: 540-52.
162. Mahadevi AS, Rahalkar AP, Gadre SR, Sastry GN. Ab initio investigation of benzene clusters: Molecular tailoring approach. J Chem Phys 2010; 133: 164308-419.
163. PDB: 2RG5. Hynes J Jr, Dyckman AJ, Lin S, et al. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogenactivated protein kinase inhibitors. J Med Chem 2008; 51: 4-16.
164. Reddy AS, Vijay D, Sastry GM, Sastry GN. From subtle to substantial: role of metal ions on pi-pi interactions. J Phys Chem B 2006; 110: 2479-81.
165. Reddy AS, Vijay D, Sastry GM, Sastry GN. Reply to "from subtle to substantial: Role of metal ions on p-p interactions". J Phys Chem B, 2006; 110: 10206-7.
166. Feng L, Geisselbrecht Y, Blanck S, et al. Structurally sophisticated octahedral metal complexes as highly selective protein kinase inhibitors. J Am Chem Soc 2011; 133: 5976-86.
167. Vijay D, Zipse H, Sastry GN. On the cooperativity of cation-and hydrogen bonding interactions. J Phys Chem B 2008; 112: 8863-7.
168. Vijay D, Sastry GN. The cooperativity of cation-and β-interactions. Chem Phys Lett 2010; 485: 235-42.
169. Dinadayalane TC, Sastry GN, Leszczynski J. A comprehensive theoretical study towards the accurate proton affinity values of naturally occurring amino acid. Int J Quant Chem, 2006; 106: 2920-33.
170. Hubbard SR, Wei L, Ellis L, Hendrickson WA. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 1994; 372: 746-54.
171. Cumming JG, McKenzie CL, Bowden SG, et al. Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase. Bioorg Med Chem Lett 2004; 14: 5389-94.
172. Heron NM, Anderson M, Blowers DP, et al. SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. Bioorg Med Chem Lett 2006; 16: 1320-3.
173. Martin MP, Zhu JY, Lawrence HR, et al. A novel mechanism by which small molecule inhibitors induce the DFG flip in Aurora A. ACS Chem Biol 2012; 7: 698-706.
174. Bukhtiyarova M, Karpusas M, Northrop K, Namboodiri HV, Springman EB. Mutagenesis of p38alpha MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-OUT state. Biochemistry 2007; 46: 5687-96.
175. de Beer SB, Vermeulen NP, Oostenbrink C. The role of water molecules in computational drug design. Curr Top Med Chem 2010; 10: 55-66.
176. Knight JD, Hamelberg D, McCammon JA, Kothary R. The role of conserved water molecules in the catalytic domain of protein kinases. Proteins 2009; 76: 527-35.
177. Neela YI, Mahadevi AS, Sastry GN. Hydrogen bonding in water clusters and their ionized counterparts. J Phys Chem B 2010; 114: 17162-71.
178. Shaltiel S, Cox S, Taylor SS. Conserved water molecules contribute to the extensive network of interactions at the active site of protein kinase A. Proc Natl Acad Sci USA 1998; 95: 484-91.
179. Lu SY, Jiang YJ, Lv J, Zou JW, Wu TX. Role of bridging water molecules in GSK3 β-inhibitor complexes: insights from QM/MM, MD, and molecular docking studies. J Comput Chem 2011; 32: 1907-18.
180. Barillari C, Duncan AL, Westwood IM, Blagg J, van Montfort RL. Analysis of water patterns in protein kinase binding sites. Proteins 2011; 79: 2109-21.
181. Fernandez A, Sanguino A, Peng Z, et al. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest 2007; 117: 4044-54.
182. Myrianthopoulos V, Magiatis P, Ferandin Y, Skaltsounis AL, Meijer L, Mikros E. An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins. J Med Chem 2007; 50: 4027-37.
183. Finlay MR, Acton DG, Andrews DM, et al. Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode. Bioorg Med Chem Lett 2008; 18: 4442-6.
184. Wissner A, Berger DM, Boschelli DH, et al. 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors. J Med Chem 2000; 43: 3244-56.
185. Zhang B, Tan VB, Lim KM, Tay TE. Significance of water molecules in the inhibition of cylin-dependent kinase 2 and 5 complexes. J Chem Inf Model 2007; 47: 1877-85.
186. de Courcy B, Piquemal JP, Garbay C, Gresh N. Polarizable water molecules in ligand-macromolecule recognition. Impact on the relative affinities of competing pyrrolopyrimidine inhibitors for FAK kinase. J Am Chem Soc 2010; 132: 3312-20.
187. Luccarelli J, Michel J, Tirado-Rives J, Jorgensen WL. Effects of Water Placement on Predictions of binding affinities for p38 MAP kinase inhibitors. J Chem Theory Comput 2010; 6: 3850-6.
188. Robinson DD, Sherman W, Farid R. Understanding kinase selectivity through energetic analysis of binding site waters. Chem Med Chem 2010; 5: 618-27.
189. Luo Y. Selectivity assessment of kinase inhibitors: strategies and challenges. Curr Opin Mol Ther 2005; 7: 251-5.
190. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127-32.
191. Posy SL, Hermsmeier MA, Vaccaro W, et al. Trends in kinase selectivity: insights for target class-focused library screening. J Med Chem 2011; 54: 54-66.
192. Davis MI, Hunt JP, Herrgard S, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011; 29: 1046-51.
193. Norman RA, Toader D, Ferguson AD. Structural approaches to obtain kinase selectivity. Trends Pharmacol Sci 2012; 33: 273-8.
194. Traxler P, Furet P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol Ther 1999; 82: 195-206.
195. Smaill JB, Rewcastle GW, Loo JA, et al. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline-and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilising functions. J Med Chem 2000; 43: 1380-97.
196. Swahn BM, Huerta F, Kallin E, et al. Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3. Bioorg Med Chem Lett 2005; 15: 5095-9.
197. Subramanian G, Sud M. Computational modeling of kinase inhibitor selectivity. ACS Med Chem Lett 2010; 1: 395-9.
198. Sheinerman FB, Giraud E, Laoui A. High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding. J Mol Biol 2005; 352: 1134-56.
199. Sastry M, Lowrie JF, Dixon SL, Sherman W. Large-scale systematic analysis of 2D fingerprint methods and parameters to improve virtual screening enrichments. J Chem Inf Model. 2010; 50: 771-84.
200. Singh J, Deng Z, Narale G, Chuaqui C. Structural interaction fingerprints: a new approach to organizing, mining, analyzing, and designing protein-small molecule complexes. Chem Biol Drug Des. 2006; 67: 5-12.
201. Kelly MD, Mancera RL. Expanded interaction fingerprint method for analyzing ligand binding modes in docking and structure-based drug design. J Chem Inf Comput Sci 2004; 44: 1942-51.
202. Baroni M, Cruciani G, Sciabola S, Perruccio F, Mason JS. A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for Ligands and Proteins (FLAP): theory and application. J Chem Inf Model 2007; 47: 279-94.
203. Tan L, Lounkine E, Bajorath J. Similarity searching using fingerprints of molecular fragments involved in protein-ligand interactions. J Chem Inf Model 2008; 48: 2308-12.
204. Schlosser J, Rarey M. Beyond the virtual screening paradigm: structure-based searching for new lead compounds. J Chem Inf Model 2009; 49: 800-9.
205. Ghemtio L, Devignes MD, Smaïl-Tabbone M, Souchet M, Leroux V, Maigret B. Comparison of three preprocessing filters efficiency in virtual screening: identification of new putative LXRbeta regulators as a test case. J Chem Inf Model 2010; 50: 701-15.
206. Ma XH, Wang R, Tan CY, et al. Virtual screening of selective multitarget kinase inhibitors by combinatorial support vector machines. Mol Pharm 2010; 7: 1545-60.
207. Musafia B, Senderowitz H. Bioactive conformational biasing: A new method for focusing conformational ensembles on bioactivelike conformers. J Chem Inf Model 2009; 49: 2469-80.
208. Goldberg DR, Hao MH, Qian KC, et al. Discovery and optimization of p38 inhibitors via computer-assisted drug design. J Med Chem 2007; 50: 4016-26.
209. Regan J, Capolino A, Cirillo PF, et al. Structure-activity relationships of the p38r MAP kinase inhibitor 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy) naphthalen-1-yl]urea (BIRB 796). J Med Chem 2003; 46: 4676-86.
210. Dominguez C, Tamayo N, Zhang D. p38 Inhibitors: Beyond pyridinylimidazoles. Expert Opin Ther Pat 2005; 15: 801-16.
211. Wang R, Gao Y, Lai L. LigBuilder: A multi-purpose program for structure-based drug design. J Mol Model 2000; 6: 498-516.
212. Vieth M, Erickson J, Wang J, et al. Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches. J Med Chem 2009; 52: 6456-66.
213. Bamborough P, Brown MJ, Christopher JA, Chung CW, Mellor GW. Selectivity of kinase inhibitor fragments. J Med Chem 2001; 54: 5131-43.
214. Pegg SC, Haresco JJ, Kuntz ID. A genetic algorithm for structurebased de novo design. J Comput Aided Mol Des 2001; 15: 911-33.
215. Douguet D, Munier-Lehmann H, Labesse G, Pochet S. LEA3D: A computer-aided ligand design for structure-based drug design. J Med Chem 2005; 48: 2457-2468.
216. Yuan Y, Pei J, Lai L. LigBuilder 2: A practical de novo drug design approach. J Chem Inf Model 2011; 51: 1083-91.
217. Todorov NP, Dean PM. Evaluation of a method for controlling molecular scaffold diversity in de novo ligand design. J Comput Aided Mol Des 1997; 11: 175-92.
218. DeWitte R, Ishchenko A, Shakhnovich E. SMoG: de novo design method based on simple, fast, and accurate free energy estimates.2. Case studies on molecular design. J Am Chem Soc 1997; 119: 4608-17.
219. Gillet VJ, Newell W, Mata P, et al. SPROUT: Recent developments in the de novo design of molecules. J Chem Inf Comput Sci 1994; 34: 207-17.
220. Dey F, Caflisch A. Fragment-based de novo ligand design by multiobjective evolutionary optimization. J Chem Inf Mod 2008; 48: 679-90.
221. Dalgarno D, Stehle T, Narula S, et al. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds. Chem Biol Drug Des 2006; 67: 46-57.
222. Yang Y, Qin J, Liu H, Yao X. Molecular dynamics simulation, free energy calculation and structure-based 3D-QSAR studies of BRAF kinase inhibitors. J Chem Inf Model 2011; 51: 680-92.
223. Fabian MA, et al. A small molecule kinase interaction map for clinical kinase inhibitors, Nat Biotechnol 2005; 23: 329-36.
224. Fernández A, Rogale K, Scott RL, Scheraga HA. Inhibitor design by wrapping packing defects in HIV-1 proteins. Proc Natl Acad Sci USA 2004; 101: 11640-5.
225. Maddipati S, Fernández A. Feature-similarity protein classifier as a ligand engineering tool. Biomol Eng 2006; 2: 307-315.
226. Bregman H, Carroll PJ, Meggers E. Rapid access to unexplored chemical space by ligand scanning around a ruthenium center: discovery of potent and selective protein kinase inhibitors. J Am Chem Soc 2006; 128: 877-84.
227. Maksimoska J, Feng L, Harms K, et al. Targeting large kinase active site with rigid, bulky octahedral ruthenium complexes. J Am Chem Soc 2008; 130: 15764-5.
228. Wilbuer A, Vlecken DH, Schmitz DJ, et al. Iridium complex with antiangiogenic properties. Angew Chem Int Ed Engl 2010; 49: 3839-42.
229. Badrinarayan P, Srivani P, Sastry GN. Design of 1-arylsulfamido-2-alkylpiperazine derivatives as secreted PLA2 inhibitors. J Mol Model 2011; 17: 817-31.
230. Srivani P, Kiran K, Sastry GN. Understanding the structural requirements of triarylethane analogues towards PDE-IV inhibitors: A molecular modeling study. Ind J Chem A 2006; 45A: 68-76.
231. Srivani P, Srinivas E, Raghu R, Sastry GN. Molecular modeling studies of pyridopurinone derivatives-Potential phosphodiesterase5 inhibitors. J Mol Graph Model 2007; 26: 378-90.
232. Kulkarni GK, Srivani P, Achiah G, Sastry GN. Strategies to design pyrazolyl urea derivatives for p38 kinase inhibition: A molecular modeling study. J Comp-Aided Mol Des 2007; 21: 155-66.
233. Janardhan S, Srivani P, Sastry GN. 2D and 3D quantitative structure-activity relationship studies on a series of bis-pyridinium compounds as choline kinase inhibitors. QSAR & Comb Sci 2006; 25: 860-72.
234. Romeiroa NC, Albuquerque MG, Alencastro RB, Ravib M, Hopfinger AJ. Construction of 4D-QSAR models for use in the design of novel p38-MAPK inhibitors. J Comput-Aided Mol Des 2005; 19: 385-400.
235. Romeiroa NC, Albuquerque MG, Alencastro RB, Ravib M, Hopfinger AJ. Free-energy force-field three-dimensional quantitative structure-activity relationship analysis of a set of p38-mitogen activated protein kinase inhibitors. J Mol Model 2006; 12: 855-68.
236. Du QS, Huang RB, Wei YT, Pang ZW, Du LQ, Chou KC. Fragment-based quantitative structure-activity relationship (FB-QSAR) for fragment-based drug design. J Comput Chem 2009; 30: 295-304.
237. Srinivas E, Murthy JN, Rao AR, Sastry GN. Recent advances in molecular modeling and medicinal chemistry aspects of phosphoglycoprotein. Curr Drug Metab, 2006; 7: 205-17.
238. Ravindra GK, Achaiah G, Sastry GN. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking. Eur J Med Chem 2008; 43: 830-8.